Computer Woes
I think I posted awhile back that I had switched computers. I built myself a fairly modern Windows PC (fast, lots of memory, etc. I will spare you the geek speak). But from near the beginning it gave me the dreaded "Blue Screen of Death" every now & then. I finally narrowed it down (I think) to overheating. A new CPU fan and two more case fans and it runs 30 degrees F cooler. Yeah!
But the machine remained unstable, crashing on random programs. Today I did a Windows repair install. So far so good, we'll see.
I reloaded Frontpage and plan on making some enhancements to the main website (as long as things are stable). Keep an eye out. The Blog has remained unaffected as I post many updates while eating lunch at work.
I appreciate your patience in the test of my engineering skills :-) Mike
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
